Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus Therapeutics expects interim results for LUNAR-CF and LUNAR-OTC in 2025. Learn why ARCT stock presents an ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on ARCT stock, giving a Buy rating on November 8. Discover the latest stocks recommended by top Wall Street analysts, ...

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The ...

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) in a research report ...

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have earned an average recommendation of “Buy” ...

1 strain in Japan and for the continued success of the STARR® platform in multiple Phase 3 trials, underscoring CSL and Arcturus’ commitment to deliver disruptive technologies for protection ...

Earlier this week, authorities confirmed that a 17-year-old boy has been charged with murder in the shooting. Mobile police ...

Forty-four-year-old Anthony Green is accused of shooting another man multiple times during an argument on Nov. 4, 2024. Nyyon ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...